Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, SBS

Former MLB Player, Eric King, Joins NuLife Ventures


CHATTANOOGA, Tenn., Feb. 17, 2020 /PRNewswire/ -- NuLife Ventures (nulifeventures.com) announces that former Major League Baseball player, Eric King has joined NuLife Ventures of Chattanooga. Mr. King became an athletic spokesperson and consumer of NuLife Ventures' acclaimed product line which includes the FDA cleared AVACEN medical device.

Mr. King is one of a growing list of top influencers to join NuLife Ventures' initiative where consumers can learn more about its health and wellness products from professional athletes and other experts. The flagship product, the AVACEN 100 has already earned endorsements from former UFC Heavy Weight Champion, Bas Rutten, Olympic Gold Medalist, Kaitlin Sandeno Hogan, and others.

Mr. King played for three MLB teams during his career: the Detroit Tigers, the Chicago White Sox, and the Cleveland Indians. Highlights from his collegiate career include hitting .667 in the College World Series and selection to the All-Decade Team at the University of Tennessee. During his long career in baseball, and while establishing himself as a trusted wellness expert, he has sought after a no-medication pain relief treatment for himself and clients. That search has brought him to NuLife Ventures and the AVACEN medical device.

Mr. King, impressed with the AVACEN's science, research, case studies, and track record, said, "I have been inviting people to try this device." Confidently, he feels that he is providing a real solution for his clients. He went on to say, "The AVACEN has been a great tool and resource for my muscle relaxation post workouts. Additionally, I use the device for preventative pain. It's equally  important to not only take care of your body when you experience pain but also to use it preventatively before you reach the point of having pain."

About NuLife Ventures
NuLife Ventures' mission is to harness advanced technologies to redefine health and longevity. We represent best-in-class products that enable people to lead longer, healthier lives.

Information on NuLife Ventures and the AVACEN medical device can be found at http://nulifeventures.com.

Media Contact
Bob Doran ext. 101
(800) 398-9842
[email protected]

Disclaimer: These are first-person testimonials. Results may vary from person to person. Check with your licensed healthcare provider before using this or any new wellness or medical device

SOURCE NuLife Ventures


These press releases may also interest you

at 08:30
Munich Re Life US and Clareto today announced a new digital solution, Automated EHR Summarizer, which provides an intelligent and intuitive synopsis of electronic health record (EHR) data in two formats: an easy-to-use human-readable html report and...

at 08:30
Agilysys, Inc. , a leading global provider of hospitality software solutions and services, today debuted revenue optimization enhancements leveraging AI technology incorporated in Agilysys Spa. These new revenue optimization capabilities, powered by...

at 08:30
RAD AI, the leader in AI-powered audience-first marketing and communications solutions, today unveiled its new strategy to rapidly reform the industry's landscape: Artificial Intelligence Buyouts (AIBOs). This strategic endeavor is designed to...

at 08:30
Outpost (www.outpost.us), a leading network of managed semi-truck parking facilities, today announced that it has raised $12.5 million in Series A funding, led by GreenPoint Partners with support from Speedwagon Capital Partners, to accelerate...

at 08:30
Alto Neuroscience, Inc. ("Alto") today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS). Results from the study...

at 08:30
Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDxtm endometriosis diagnostic test. Per protocol data from the first 38 patients who have been enrolled in the 60 patient study...



News published on and distributed by: